#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Eosinophils are a subset of granulocytes mostly known for their capacity to stimulate allergic reactions and to fight parasites .
2-1	16-27	Eosinophils	abstract	new	coref	2-3[3_0]
2-2	28-31	are	_	_	_	_
2-3	32-33	a	abstract[3]	giv[3]	coref	4-17[0_3]
2-4	34-40	subset	abstract[3]	giv[3]	_	_
2-5	41-43	of	abstract[3]	giv[3]	_	_
2-6	44-56	granulocytes	abstract[3]|abstract	giv[3]|new	ana	2-10
2-7	57-63	mostly	_	_	_	_
2-8	64-69	known	_	_	_	_
2-9	70-73	for	_	_	_	_
2-10	74-79	their	abstract|abstract[6]	giv|new[6]	_	_
2-11	80-88	capacity	abstract[6]	new[6]	_	_
2-12	89-91	to	_	_	_	_
2-13	92-101	stimulate	_	_	_	_
2-14	102-110	allergic	event[7]	new[7]	_	_
2-15	111-120	reactions	event[7]	new[7]	_	_
2-16	121-124	and	_	_	_	_
2-17	125-127	to	_	_	_	_
2-18	128-133	fight	_	_	_	_
2-19	134-143	parasites	animal	new	_	_
2-20	144-145	.	_	_	_	_

#Text=Under normal conditions , these cells are relatively rare representing 1 – 3 % of total white blood cells .
3-1	146-151	Under	_	_	_	_
3-2	152-158	normal	abstract[9]	new[9]	coref	4-2[15_9]
3-3	159-169	conditions	abstract[9]	new[9]	_	_
3-4	170-171	,	_	_	_	_
3-5	172-177	these	object[10]	new[10]	coref	3-16[14_10]
3-6	178-183	cells	object[10]	new[10]	_	_
3-7	184-187	are	_	_	_	_
3-8	188-198	relatively	_	_	_	_
3-9	199-203	rare	_	_	_	_
3-10	204-216	representing	_	_	_	_
3-11	217-218	1	quantity	new	_	_
3-12	219-220	–	_	_	_	_
3-13	221-222	3	quantity[12]	new[12]	_	_
3-14	223-224	%	quantity[12]	new[12]	_	_
3-15	225-227	of	quantity[12]	new[12]	_	_
3-16	228-233	total	quantity[12]|object[14]	new[12]|giv[14]	coref	4-35[27_14]
3-17	234-239	white	quantity[12]|object[14]	new[12]|giv[14]	_	_
3-18	240-245	blood	quantity[12]|substance|object[14]	new[12]|new|giv[14]	_	_
3-19	246-251	cells	quantity[12]|object[14]	new[12]|giv[14]	_	_
3-20	252-253	.	_	_	_	_

#Text=During certain inflammatory conditions ( i. e. , allergies , parasitic infections , autoimmune diseases ) eosinophils can rapidly increase , due to both de novo generation from bone marrow precursors and proliferation of tissue-resident cells , infiltrating inflamed tissues , including tumors .
4-1	254-260	During	_	_	_	_
4-2	261-268	certain	abstract[15]	giv[15]	_	_
4-3	269-281	inflammatory	abstract[15]	giv[15]	_	_
4-4	282-292	conditions	abstract[15]	giv[15]	_	_
4-5	293-294	(	_	_	_	_
4-6	295-297	i.	_	_	_	_
4-7	298-300	e.	_	_	_	_
4-8	301-302	,	_	_	_	_
4-9	303-312	allergies	abstract	new	_	_
4-10	313-314	,	_	_	_	_
4-11	315-324	parasitic	event[17]	new[17]	_	_
4-12	325-335	infections	event[17]	new[17]	_	_
4-13	336-337	,	_	_	_	_
4-14	338-348	autoimmune	abstract[18]	new[18]	_	_
4-15	349-357	diseases	abstract[18]	new[18]	_	_
4-16	358-359	)	_	_	_	_
4-17	360-371	eosinophils	substance	giv	coref	6-4
4-18	372-375	can	_	_	_	_
4-19	376-383	rapidly	_	_	_	_
4-20	384-392	increase	_	_	_	_
4-21	393-394	,	_	_	_	_
4-22	395-398	due	_	_	_	_
4-23	399-401	to	_	_	_	_
4-24	402-406	both	abstract[22]	new[22]	_	_
4-25	407-409	de	object|abstract[22]	new|new[22]	_	_
4-26	410-414	novo	object|abstract[22]	new|new[22]	_	_
4-27	415-425	generation	abstract[22]	new[22]	_	_
4-28	426-430	from	abstract[22]	new[22]	_	_
4-29	431-435	bone	abstract[22]|object|object[25]	new[22]|new|new[25]	coref	16-22
4-30	436-442	marrow	abstract[22]|animal|object[25]	new[22]|new|new[25]	coref	16-21[139_0]
4-31	443-453	precursors	abstract[22]|object[25]	new[22]|new[25]	_	_
4-32	454-457	and	abstract[22]	new[22]	_	_
4-33	458-471	proliferation	abstract[22]|event[26]	new[22]|new[26]	_	_
4-34	472-474	of	abstract[22]|event[26]	new[22]|new[26]	_	_
4-35	475-490	tissue-resident	abstract[22]|event[26]|object[27]	new[22]|new[26]|giv[27]	coref	8-43[69_27]
4-36	491-496	cells	abstract[22]|event[26]|object[27]	new[22]|new[26]|giv[27]	_	_
4-37	497-498	,	_	_	_	_
4-38	499-511	infiltrating	_	_	_	_
4-39	512-520	inflamed	object[28]	new[28]	coref	8-57[0_28]
4-40	521-528	tissues	object[28]	new[28]	_	_
4-41	529-530	,	_	_	_	_
4-42	531-540	including	_	_	_	_
4-43	541-547	tumors	object	new	coref	5-8[32_0]
4-44	548-549	.	_	_	_	_

#Text=Tumor-associated tissue eosinophilia has been described in various solid tumors although its prognostic value in clinical oncology remains controversial .
5-1	550-566	Tumor-associated	abstract[31]	new[31]	ana	5-12[0_31]
5-2	567-573	tissue	object|abstract[31]	new|new[31]	_	_
5-3	574-586	eosinophilia	abstract[31]	new[31]	_	_
5-4	587-590	has	_	_	_	_
5-5	591-595	been	_	_	_	_
5-6	596-605	described	_	_	_	_
5-7	606-608	in	_	_	_	_
5-8	609-616	various	object[32]	giv[32]	_	_
5-9	617-622	solid	object[32]	giv[32]	_	_
5-10	623-629	tumors	object[32]	giv[32]	_	_
5-11	630-638	although	_	_	_	_
5-12	639-642	its	abstract|abstract[34]	giv|new[34]	_	_
5-13	643-653	prognostic	abstract[34]	new[34]	_	_
5-14	654-659	value	abstract[34]	new[34]	_	_
5-15	660-662	in	abstract[34]	new[34]	_	_
5-16	663-671	clinical	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-17	672-680	oncology	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-18	681-688	remains	_	_	_	_
5-19	689-702	controversial	_	_	_	_
5-20	703-704	.	_	_	_	_

#Text=In vivo , eosinophils were shown to exert a protective role inhibiting tumor growth in mouse models of melanoma , colorectal cancer , hepatocellular carcinoma , and inducible fibrosarcoma .
6-1	705-707	In	_	_	_	_
6-2	708-712	vivo	abstract	new	_	_
6-3	713-714	,	_	_	_	_
6-4	715-726	eosinophils	substance	giv	coref	7-3
6-5	727-731	were	_	_	_	_
6-6	732-737	shown	_	_	_	_
6-7	738-740	to	_	_	_	_
6-8	741-746	exert	_	_	_	_
6-9	747-748	a	abstract[38]	new[38]	coref	20-21[169_38]
6-10	749-759	protective	abstract[38]	new[38]	_	_
6-11	760-764	role	abstract[38]	new[38]	_	_
6-12	765-775	inhibiting	_	_	_	_
6-13	776-781	tumor	abstract|abstract[40]	new|new[40]	coref|coref	13-20|18-7[149_40]
6-14	782-788	growth	abstract[40]	new[40]	_	_
6-15	789-791	in	_	_	_	_
6-16	792-797	mouse	animal|abstract[42]	new|new[42]	_	_
6-17	798-804	models	abstract[42]	new[42]	_	_
6-18	805-807	of	abstract[42]	new[42]	_	_
6-19	808-816	melanoma	abstract[42]|abstract	new[42]|new	coref	15-17
6-20	817-818	,	abstract[42]	new[42]	_	_
6-21	819-829	colorectal	abstract[42]|abstract[44]	new[42]|new[44]	coref	14-18[0_44]
6-22	830-836	cancer	abstract[42]|abstract[44]	new[42]|new[44]	_	_
6-23	837-838	,	abstract[42]	new[42]	_	_
6-24	839-853	hepatocellular	abstract[42]|abstract|object[46]	new[42]|new|new[46]	coref|coref	9-11[0_46]|19-17
6-25	854-863	carcinoma	abstract[42]|object[46]	new[42]|new[46]	_	_
6-26	864-865	,	abstract[42]	new[42]	_	_
6-27	866-869	and	abstract[42]	new[42]	_	_
6-28	870-879	inducible	abstract[42]|abstract[47]	new[42]|new[47]	_	_
6-29	880-892	fibrosarcoma	abstract[42]|abstract[47]	new[42]|new[47]	_	_
6-30	893-894	.	_	_	_	_

#Text=Furthermore , eosinophils infiltration in the lung can prevent the formation of experimental pulmonary metastasis .
7-1	895-906	Furthermore	_	_	_	_
7-2	907-908	,	_	_	_	_
7-3	909-920	eosinophils	person|organization[49]	giv|new[49]	coref	8-1
7-4	921-933	infiltration	organization[49]	new[49]	_	_
7-5	934-936	in	organization[49]	new[49]	_	_
7-6	937-940	the	organization[49]|object[50]	new[49]|new[50]	coref	15-23[0_50]
7-7	941-945	lung	organization[49]|object[50]	new[49]|new[50]	_	_
7-8	946-949	can	_	_	_	_
7-9	950-957	prevent	_	_	_	_
7-10	958-961	the	event[51]	new[51]	_	_
7-11	962-971	formation	event[51]	new[51]	_	_
7-12	972-974	of	event[51]	new[51]	_	_
7-13	975-987	experimental	event[51]|event[53]	new[51]|new[53]	coref	18-10[150_53]
7-14	988-997	pulmonary	event[51]|person|event[53]	new[51]|new|new[53]	_	_
7-15	998-1008	metastasis	event[51]|event[53]	new[51]|new[53]	_	_
7-16	1009-1010	.	_	_	_	_

#Text=Eosinophils are equipped with granules carrying a plethora of cytotoxic mediators , such as the cationic proteins major basic protein ( MBP ) , eosinophil cationic protein ( ECP ) , eosinophil peroxidase ( EPX ) , and granzymes ( granzyme-A in human cells , granzyme-B in murine cells ) that can destroy target cells or tissues .
8-1	1011-1022	Eosinophils	place	giv	coref	9-3
8-2	1023-1026	are	_	_	_	_
8-3	1027-1035	equipped	_	_	_	_
8-4	1036-1040	with	_	_	_	_
8-5	1041-1049	granules	object	new	coref	23-21[198_0]
8-6	1050-1058	carrying	_	_	_	_
8-7	1059-1060	a	abstract[56]	new[56]	_	_
8-8	1061-1069	plethora	abstract[56]	new[56]	_	_
8-9	1070-1072	of	abstract[56]	new[56]	_	_
8-10	1073-1082	cytotoxic	abstract[56]|person[57]	new[56]|new[57]	_	_
8-11	1083-1092	mediators	abstract[56]|person[57]	new[56]|new[57]	_	_
8-12	1093-1094	,	_	_	_	_
8-13	1095-1099	such	_	_	_	_
8-14	1100-1102	as	_	_	_	_
8-15	1103-1106	the	substance[58]|substance[59]	new[58]|new[59]	coref	8-25[62_59]
8-16	1107-1115	cationic	substance[58]|substance[59]	new[58]|new[59]	_	_
8-17	1116-1124	proteins	substance[58]|substance[59]	new[58]|new[59]	_	_
8-18	1125-1130	major	substance[59]	new[59]	_	_
8-19	1131-1136	basic	substance[59]	new[59]	_	_
8-20	1137-1144	protein	substance[59]	new[59]	_	_
8-21	1145-1146	(	_	_	_	_
8-22	1147-1150	MBP	object	new	_	_
8-23	1151-1152	)	_	_	_	_
8-24	1153-1154	,	_	_	_	_
8-25	1155-1165	eosinophil	substance[62]	giv[62]	coref	13-8[0_62]
8-26	1166-1174	cationic	abstract|substance[62]	new|giv[62]	_	_
8-27	1175-1182	protein	substance[62]	giv[62]	_	_
8-28	1183-1184	(	_	_	_	_
8-29	1185-1188	ECP	object	new	_	_
8-30	1189-1190	)	_	_	_	_
8-31	1191-1192	,	_	_	_	_
8-32	1193-1203	eosinophil	abstract|abstract[65]	new|new[65]	appos	8-35[0_65]
8-33	1204-1214	peroxidase	abstract[65]	new[65]	_	_
8-34	1215-1216	(	_	_	_	_
8-35	1217-1220	EPX	abstract	giv	_	_
8-36	1221-1222	)	_	_	_	_
8-37	1223-1224	,	_	_	_	_
8-38	1225-1228	and	_	_	_	_
8-39	1229-1238	granzymes	substance	new	_	_
8-40	1239-1240	(	_	_	_	_
8-41	1241-1251	granzyme-A	abstract[68]	new[68]	coref	9-16[0_68]
8-42	1252-1254	in	abstract[68]	new[68]	_	_
8-43	1255-1260	human	abstract[68]|object[69]	new[68]|giv[69]	coref	8-54[72_69]
8-44	1261-1266	cells	abstract[68]|object[69]	new[68]|giv[69]	_	_
8-45	1267-1268	,	abstract[68]|object[69]	new[68]|giv[69]	_	_
8-46	1269-1279	granzyme-B	abstract[68]|object[69]|abstract[70]	new[68]|giv[69]|new[70]	_	_
8-47	1280-1282	in	abstract[68]|object[69]|abstract[70]	new[68]|giv[69]|new[70]	_	_
8-48	1283-1289	murine	abstract[68]|object[69]|abstract[70]|substance	new[68]|giv[69]|new[70]|new	_	_
8-49	1290-1295	cells	abstract[68]|object[69]|abstract[70]	new[68]|giv[69]|new[70]	_	_
8-50	1296-1297	)	_	_	_	_
8-51	1298-1302	that	_	_	_	_
8-52	1303-1306	can	_	_	_	_
8-53	1307-1314	destroy	_	_	_	_
8-54	1315-1321	target	object[72]	giv[72]	coref	9-9[77_72]
8-55	1322-1327	cells	object[72]	giv[72]	_	_
8-56	1328-1330	or	object[72]	giv[72]	_	_
8-57	1331-1338	tissues	object[72]|object	giv[72]|giv	_	_
8-58	1339-1340	.	_	_	_	_

#Text=Indeed , eosinophils were shown to directly kill human colon carcinoma cells via release of granzyme-A in a mechanism dependent on the integrin CD11a/CD18 and on the cytokine IL-18 .
9-1	1341-1347	Indeed	_	_	_	_
9-2	1348-1349	,	_	_	_	_
9-3	1350-1361	eosinophils	abstract	giv	coref	10-4
9-4	1362-1366	were	_	_	_	_
9-5	1367-1372	shown	_	_	_	_
9-6	1373-1375	to	_	_	_	_
9-7	1376-1384	directly	_	_	_	_
9-8	1385-1389	kill	_	_	_	_
9-9	1390-1395	human	object[77]	giv[77]	coref	10-16[92_77]
9-10	1396-1401	colon	object|object[77]	new|giv[77]	_	_
9-11	1402-1411	carcinoma	object|object[77]	giv|giv[77]	_	_
9-12	1412-1417	cells	object[77]	giv[77]	_	_
9-13	1418-1421	via	_	_	_	_
9-14	1422-1429	release	event[78]	new[78]	_	_
9-15	1430-1432	of	event[78]	new[78]	_	_
9-16	1433-1443	granzyme-A	event[78]|abstract	new[78]|giv	_	_
9-17	1444-1446	in	_	_	_	_
9-18	1447-1448	a	abstract[80]	new[80]	_	_
9-19	1449-1458	mechanism	abstract[80]	new[80]	_	_
9-20	1459-1468	dependent	_	_	_	_
9-21	1469-1471	on	_	_	_	_
9-22	1472-1475	the	object[82]	new[82]	_	_
9-23	1476-1484	integrin	person|object[82]	new|new[82]	_	_
9-24	1485-1495	CD11a/CD18	object[82]	new[82]	_	_
9-25	1496-1499	and	_	_	_	_
9-26	1500-1502	on	_	_	_	_
9-27	1503-1506	the	place[84]	new[84]	_	_
9-28	1507-1515	cytokine	abstract|place[84]	new|new[84]	_	_
9-29	1516-1521	IL-18	place[84]	new[84]	_	_
9-30	1522-1523	.	_	_	_	_

#Text=In addition , eosinophils activated by cross-linking of the receptor 2B4/CD244 exhibited tumoricidal activities against human B lymphoma cells .
10-1	1524-1526	In	_	_	_	_
10-2	1527-1535	addition	_	_	_	_
10-3	1536-1537	,	_	_	_	_
10-4	1538-1549	eosinophils	substance	giv	coref	13-17
10-5	1550-1559	activated	_	_	_	_
10-6	1560-1562	by	_	_	_	_
10-7	1563-1576	cross-linking	abstract[86]	new[86]	_	_
10-8	1577-1579	of	abstract[86]	new[86]	_	_
10-9	1580-1583	the	abstract[86]|substance[87]	new[86]|new[87]	_	_
10-10	1584-1592	receptor	abstract[86]|substance[87]	new[86]|new[87]	_	_
10-11	1593-1602	2B4/CD244	abstract	new	_	_
10-12	1603-1612	exhibited	_	_	_	_
10-13	1613-1624	tumoricidal	abstract[89]	new[89]	coref	14-22[117_89]
10-14	1625-1635	activities	abstract[89]	new[89]	_	_
10-15	1636-1643	against	abstract[89]	new[89]	_	_
10-16	1644-1649	human	abstract[89]|object[92]	new[89]|giv[92]	coref	20-17[167_92]
10-17	1650-1651	B	abstract[89]|person|object[92]	new[89]|new|giv[92]	_	_
10-18	1652-1660	lymphoma	abstract[89]|abstract|object[92]	new[89]|new|giv[92]	_	_
10-19	1661-1666	cells	abstract[89]|object[92]	new[89]|giv[92]	_	_
10-20	1667-1668	.	_	_	_	_

#Text=It appears that the process of adhesion through integrins is important for eosinophil activation during inflammation .
11-1	1669-1671	It	_	_	_	_
11-2	1672-1679	appears	_	_	_	_
11-3	1680-1684	that	_	_	_	_
11-4	1685-1688	the	abstract[93]	new[93]	_	_
11-5	1689-1696	process	abstract[93]	new[93]	_	_
11-6	1697-1699	of	abstract[93]	new[93]	_	_
11-7	1700-1708	adhesion	abstract[93]|abstract	new[93]|new	coref	12-7[100_0]
11-8	1709-1716	through	abstract[93]	new[93]	_	_
11-9	1717-1726	integrins	abstract[93]|substance	new[93]|new	_	_
11-10	1727-1729	is	_	_	_	_
11-11	1730-1739	important	_	_	_	_
11-12	1740-1743	for	_	_	_	_
11-13	1744-1754	eosinophil	abstract[96]	new[96]	coref	21-13[0_96]
11-14	1755-1765	activation	abstract[96]	new[96]	_	_
11-15	1766-1772	during	_	_	_	_
11-16	1773-1785	inflammation	abstract	new	_	_
11-17	1786-1787	.	_	_	_	_

#Text=However , it is unclear whether cell adhesion and degranulation are sequential or independent events .
12-1	1788-1795	However	_	_	_	_
12-2	1796-1797	,	_	_	_	_
12-3	1798-1800	it	abstract	new	cata	12-3[0_102]
12-4	1801-1803	is	_	_	_	_
12-5	1804-1811	unclear	_	_	_	_
12-6	1812-1819	whether	abstract[102]	new[102]	_	_
12-7	1820-1824	cell	place|abstract[100]|abstract[102]	new|giv[100]|new[102]	coref	22-7
12-8	1825-1833	adhesion	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
12-9	1834-1837	and	abstract[102]	new[102]	_	_
12-10	1838-1851	degranulation	event|abstract[102]	new|new[102]	_	_
12-11	1852-1855	are	abstract[102]	new[102]	_	_
12-12	1856-1866	sequential	abstract[102]	new[102]	_	_
12-13	1867-1869	or	_	_	_	_
12-14	1870-1881	independent	_	_	_	_
12-15	1882-1888	events	event	new	_	_
12-16	1889-1890	.	_	_	_	_

#Text=In addition , the mechanisms of granule protein secretion ( i. e. , degranulation ) in eosinophils leading to tumor cytotoxicity remain to be defined .
13-1	1891-1893	In	_	_	_	_
13-2	1894-1902	addition	_	_	_	_
13-3	1903-1904	,	_	_	_	_
13-4	1905-1908	the	abstract[104]	new[104]	coref	21-6[171_104]
13-5	1909-1919	mechanisms	abstract[104]	new[104]	_	_
13-6	1920-1922	of	abstract[104]	new[104]	_	_
13-7	1923-1930	granule	abstract[104]|abstract[106]	new[104]|new[106]	appos	13-14[0_106]
13-8	1931-1938	protein	abstract[104]|substance|abstract[106]	new[104]|giv|new[106]	_	_
13-9	1939-1948	secretion	abstract[104]|abstract[106]	new[104]|new[106]	_	_
13-10	1949-1950	(	abstract[104]	new[104]	_	_
13-11	1951-1953	i.	abstract[104]	new[104]	_	_
13-12	1954-1956	e.	abstract[104]	new[104]	_	_
13-13	1957-1958	,	abstract[104]	new[104]	_	_
13-14	1959-1972	degranulation	abstract[104]|abstract	new[104]|giv	coref	23-18[197_0]
13-15	1973-1974	)	abstract[104]	new[104]	_	_
13-16	1975-1977	in	abstract[104]	new[104]	_	_
13-17	1978-1989	eosinophils	abstract[104]|substance	new[104]|giv	coref	16-6[134_0]
13-18	1990-1997	leading	_	_	_	_
13-19	1998-2000	to	_	_	_	_
13-20	2001-2006	tumor	abstract|abstract[110]	giv|new[110]	coref	14-30
13-21	2007-2019	cytotoxicity	abstract[110]	new[110]	_	_
13-22	2020-2026	remain	_	_	_	_
13-23	2027-2029	to	_	_	_	_
13-24	2030-2032	be	_	_	_	_
13-25	2033-2040	defined	_	_	_	_
13-26	2041-2042	.	_	_	_	_

#Text=IL-33 is an epithelial-derived “ alarmin ” playing multiple functions in Th2-related immunopathologies and recently implied in cancer immunity , exerting pro- or anti-tumoral activities , depending on the tumor type and microenvironmental factors .
14-1	2043-2048	IL-33	object	new	coref	14-3[112_0]
14-2	2049-2051	is	_	_	_	_
14-3	2052-2054	an	object[112]	giv[112]	coref	15-7[0_112]
14-4	2055-2073	epithelial-derived	object[112]	giv[112]	_	_
14-5	2074-2075	“	object[112]	giv[112]	_	_
14-6	2076-2083	alarmin	object[112]	giv[112]	_	_
14-7	2084-2085	”	object[112]	giv[112]	_	_
14-8	2086-2093	playing	_	_	_	_
14-9	2094-2102	multiple	abstract[113]	new[113]	coref	22-15[180_113]
14-10	2103-2112	functions	abstract[113]	new[113]	_	_
14-11	2113-2115	in	_	_	_	_
14-12	2116-2127	Th2-related	abstract[114]	new[114]	_	_
14-13	2128-2145	immunopathologies	abstract[114]	new[114]	_	_
14-14	2146-2149	and	_	_	_	_
14-15	2150-2158	recently	_	_	_	_
14-16	2159-2166	implied	_	_	_	_
14-17	2167-2169	in	_	_	_	_
14-18	2170-2176	cancer	abstract|event[116]	giv|new[116]	coref	15-25[131_0]
14-19	2177-2185	immunity	event[116]	new[116]	_	_
14-20	2186-2187	,	_	_	_	_
14-21	2188-2196	exerting	_	_	_	_
14-22	2197-2201	pro-	abstract[117]	giv[117]	coref	23-7[193_117]
14-23	2202-2204	or	abstract[117]	giv[117]	_	_
14-24	2205-2217	anti-tumoral	abstract[117]	giv[117]	_	_
14-25	2218-2228	activities	abstract[117]	giv[117]	_	_
14-26	2229-2230	,	_	_	_	_
14-27	2231-2240	depending	_	_	_	_
14-28	2241-2243	on	_	_	_	_
14-29	2244-2247	the	abstract[119]	new[119]	_	_
14-30	2248-2253	tumor	abstract|abstract[119]	giv|new[119]	coref	15-1
14-31	2254-2258	type	abstract[119]	new[119]	_	_
14-32	2259-2262	and	_	_	_	_
14-33	2263-2281	microenvironmental	abstract[120]	new[120]	_	_
14-34	2282-2289	factors	abstract[120]	new[120]	_	_
14-35	2290-2291	.	_	_	_	_

#Text=Tumor over-expression or exogenous administration of IL-33 promotes anti-tumor immune responses in vivo in models of melanoma , acute myeloid leukemia , lung and colorectal cancer .
15-1	2292-2297	Tumor	abstract|organization[122]	giv|new[122]	coref	18-7
15-2	2298-2313	over-expression	organization[122]	new[122]	_	_
15-3	2314-2316	or	organization[122]	new[122]	_	_
15-4	2317-2326	exogenous	organization[122]	new[122]	_	_
15-5	2327-2341	administration	organization[122]	new[122]	_	_
15-6	2342-2344	of	organization[122]	new[122]	_	_
15-7	2345-2350	IL-33	organization[122]|substance	new[122]|giv	coref	16-1
15-8	2351-2359	promotes	_	_	_	_
15-9	2360-2370	anti-tumor	abstract[125]	new[125]	_	_
15-10	2371-2377	immune	abstract|abstract[125]	new|new[125]	coref	22-42
15-11	2378-2387	responses	abstract[125]	new[125]	_	_
15-12	2388-2390	in	abstract[125]	new[125]	_	_
15-13	2391-2395	vivo	abstract[125]	new[125]	_	_
15-14	2396-2398	in	_	_	_	_
15-15	2399-2405	models	abstract[126]	new[126]	_	_
15-16	2406-2408	of	abstract[126]	new[126]	_	_
15-17	2409-2417	melanoma	abstract[126]|abstract	new[126]|giv	_	_
15-18	2418-2419	,	abstract[126]	new[126]	_	_
15-19	2420-2425	acute	abstract[126]|abstract[129]	new[126]|new[129]	_	_
15-20	2426-2433	myeloid	abstract[126]|place|abstract[129]	new[126]|new|new[129]	_	_
15-21	2434-2442	leukemia	abstract[126]|abstract[129]	new[126]|new[129]	_	_
15-22	2443-2444	,	abstract[126]	new[126]	_	_
15-23	2445-2449	lung	abstract[126]|object	new[126]|giv	coref	16-13[136_0]
15-24	2450-2453	and	abstract[126]	new[126]	_	_
15-25	2454-2464	colorectal	abstract[126]|abstract[131]	new[126]|giv[131]	coref	19-13[157_131]
15-26	2465-2471	cancer	abstract[126]|abstract[131]	new[126]|giv[131]	_	_
15-27	2472-2473	.	_	_	_	_

#Text=IL-33 drives substantial recruitment of eosinophils to inflamed sites , such as the lung , likely by promoting eosinophilopoiesis in the bone marrow .
16-1	2474-2479	IL-33	substance	giv	coref	17-4
16-2	2480-2486	drives	_	_	_	_
16-3	2487-2498	substantial	abstract[133]	new[133]	_	_
16-4	2499-2510	recruitment	abstract[133]	new[133]	_	_
16-5	2511-2513	of	abstract[133]	new[133]	_	_
16-6	2514-2525	eosinophils	abstract[133]|substance[134]	new[133]|giv[134]	coref	17-16[0_134]
16-7	2526-2528	to	abstract[133]|substance[134]	new[133]|giv[134]	_	_
16-8	2529-2537	inflamed	abstract[133]|substance[134]|place[135]	new[133]|giv[134]|new[135]	_	_
16-9	2538-2543	sites	abstract[133]|substance[134]|place[135]	new[133]|giv[134]|new[135]	_	_
16-10	2544-2545	,	abstract[133]|substance[134]|place[135]	new[133]|giv[134]|new[135]	_	_
16-11	2546-2550	such	abstract[133]|substance[134]|place[135]	new[133]|giv[134]|new[135]	_	_
16-12	2551-2553	as	abstract[133]|substance[134]|place[135]	new[133]|giv[134]|new[135]	_	_
16-13	2554-2557	the	abstract[133]|substance[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
16-14	2558-2562	lung	abstract[133]|substance[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
16-15	2563-2564	,	abstract[133]|substance[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
16-16	2565-2571	likely	abstract[133]|substance[134]|place[135]|object[136]	new[133]|giv[134]|new[135]|giv[136]	_	_
16-17	2572-2574	by	_	_	_	_
16-18	2575-2584	promoting	_	_	_	_
16-19	2585-2603	eosinophilopoiesis	abstract[137]	new[137]	_	_
16-20	2604-2606	in	abstract[137]	new[137]	_	_
16-21	2607-2610	the	abstract[137]|animal[139]	new[137]|giv[139]	_	_
16-22	2611-2615	bone	abstract[137]|object|animal[139]	new[137]|giv|giv[139]	_	_
16-23	2616-2622	marrow	abstract[137]|animal[139]	new[137]|giv[139]	_	_
16-24	2623-2624	.	_	_	_	_

#Text=In addition , IL-33 can induce eosinophil superoxide anion production and promote the survival of eosinophils .
17-1	2625-2627	In	_	_	_	_
17-2	2628-2636	addition	_	_	_	_
17-3	2637-2638	,	_	_	_	_
17-4	2639-2644	IL-33	substance	giv	coref	18-5
17-5	2645-2648	can	_	_	_	_
17-6	2649-2655	induce	_	_	_	_
17-7	2656-2666	eosinophil	abstract[143]	new[143]	_	_
17-8	2667-2677	superoxide	substance|abstract[143]	new|new[143]	_	_
17-9	2678-2683	anion	object|abstract[143]	new|new[143]	_	_
17-10	2684-2694	production	abstract[143]	new[143]	_	_
17-11	2695-2698	and	_	_	_	_
17-12	2699-2706	promote	_	_	_	_
17-13	2707-2710	the	event[144]	new[144]	_	_
17-14	2711-2719	survival	event[144]	new[144]	_	_
17-15	2720-2722	of	event[144]	new[144]	_	_
17-16	2723-2734	eosinophils	event[144]|substance	new[144]|giv	coref	20-5
17-17	2735-2736	.	_	_	_	_

#Text=We initially reported that IL-33 inhibits tumor growth and pulmonary metastasis in vivo in an eosinophil-dependent manner .
18-1	2737-2739	We	person	acc	ana	20-1
18-2	2740-2749	initially	_	_	_	_
18-3	2750-2758	reported	_	_	_	_
18-4	2759-2763	that	_	_	_	_
18-5	2764-2769	IL-33	substance	giv	coref	19-8
18-6	2770-2778	inhibits	_	_	_	_
18-7	2779-2784	tumor	abstract|abstract[149]	giv|giv[149]	coref	23-24
18-8	2785-2791	growth	abstract[149]	giv[149]	_	_
18-9	2792-2795	and	_	_	_	_
18-10	2796-2805	pulmonary	event[150]	giv[150]	_	_
18-11	2806-2816	metastasis	event[150]	giv[150]	_	_
18-12	2817-2819	in	event[150]	giv[150]	_	_
18-13	2820-2824	vivo	event[150]	giv[150]	_	_
18-14	2825-2827	in	_	_	_	_
18-15	2828-2830	an	abstract[151]	new[151]	coref	22-25[183_151]
18-16	2831-2851	eosinophil-dependent	abstract[151]	new[151]	_	_
18-17	2852-2858	manner	abstract[151]	new[151]	_	_
18-18	2859-2860	.	_	_	_	_

#Text=Subsequent studies confirmed eosinophil-mediated anti-tumoral effects of IL-33 in pre-clinical models of metastatic peritoneal cancer , hepatocellular , and prostatic cancer .
19-1	2861-2871	Subsequent	abstract[152]	new[152]	_	_
19-2	2872-2879	studies	abstract[152]	new[152]	_	_
19-3	2880-2889	confirmed	_	_	_	_
19-4	2890-2909	eosinophil-mediated	abstract[153]	new[153]	_	_
19-5	2910-2922	anti-tumoral	abstract[153]	new[153]	_	_
19-6	2923-2930	effects	abstract[153]	new[153]	_	_
19-7	2931-2933	of	abstract[153]	new[153]	_	_
19-8	2934-2939	IL-33	abstract[153]|substance	new[153]|giv	coref	20-8
19-9	2940-2942	in	abstract[153]	new[153]	_	_
19-10	2943-2955	pre-clinical	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-11	2956-2962	models	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-12	2963-2965	of	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-13	2966-2976	metastatic	abstract[153]|abstract[155]|abstract[157]	new[153]|new[155]|giv[157]	coref	19-20[159_157]
19-14	2977-2987	peritoneal	abstract[153]|abstract[155]|place|abstract[157]	new[153]|new[155]|new|giv[157]	_	_
19-15	2988-2994	cancer	abstract[153]|abstract[155]|abstract[157]	new[153]|new[155]|giv[157]	_	_
19-16	2995-2996	,	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-17	2997-3011	hepatocellular	abstract[153]|abstract[155]|abstract	new[153]|new[155]|giv	_	_
19-18	3012-3013	,	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-19	3014-3017	and	abstract[153]|abstract[155]	new[153]|new[155]	_	_
19-20	3018-3027	prostatic	abstract[153]|abstract[155]|abstract[159]	new[153]|new[155]|giv[159]	_	_
19-21	3028-3034	cancer	abstract[153]|abstract[155]|abstract[159]	new[153]|new[155]|giv[159]	_	_
19-22	3035-3036	.	_	_	_	_

#Text=Our study suggested that eosinophils recruited by IL-33 might either function as accessory cells attracting CD8 T cells or play a direct antitumor role .
20-1	3037-3040	Our	person|abstract[161]	giv|new[161]	ana	21-3
20-2	3041-3046	study	abstract[161]	new[161]	_	_
20-3	3047-3056	suggested	_	_	_	_
20-4	3057-3061	that	_	_	_	_
20-5	3062-3073	eosinophils	substance	giv	coref	21-11
20-6	3074-3083	recruited	_	_	_	_
20-7	3084-3086	by	_	_	_	_
20-8	3087-3092	IL-33	substance	giv	coref	21-15
20-9	3093-3098	might	_	_	_	_
20-10	3099-3105	either	abstract[164]	new[164]	_	_
20-11	3106-3114	function	abstract[164]	new[164]	_	_
20-12	3115-3117	as	abstract[164]	new[164]	_	_
20-13	3118-3127	accessory	abstract[164]	new[164]	_	_
20-14	3128-3133	cells	abstract[164]	new[164]	_	_
20-15	3134-3144	attracting	_	_	_	_
20-16	3145-3148	CD8	quantity	new	_	_
20-17	3149-3150	T	person|object[167]	new|giv[167]	coref	23-23[200_167]
20-18	3151-3156	cells	object[167]	giv[167]	_	_
20-19	3157-3159	or	_	_	_	_
20-20	3160-3164	play	_	_	_	_
20-21	3165-3166	a	abstract[169]	giv[169]	_	_
20-22	3167-3173	direct	abstract[169]	giv[169]	_	_
20-23	3174-3183	antitumor	abstract|abstract[169]	new|giv[169]	_	_
20-24	3184-3188	role	abstract[169]	giv[169]	_	_
20-25	3189-3190	.	_	_	_	_

#Text=Here , we further investigated the anti-tumoral mechanisms operated by eosinophils following activation with IL-33 .
21-1	3191-3195	Here	_	_	_	_
21-2	3196-3197	,	_	_	_	_
21-3	3198-3200	we	person	giv	ana	22-10
21-4	3201-3208	further	_	_	_	_
21-5	3209-3221	investigated	_	_	_	_
21-6	3222-3225	the	abstract[171]	giv[171]	_	_
21-7	3226-3238	anti-tumoral	abstract[171]	giv[171]	_	_
21-8	3239-3249	mechanisms	abstract[171]	giv[171]	_	_
21-9	3250-3258	operated	_	_	_	_
21-10	3259-3261	by	_	_	_	_
21-11	3262-3273	eosinophils	substance	giv	coref	22-18[181_0]
21-12	3274-3283	following	_	_	_	_
21-13	3284-3294	activation	abstract	giv	_	_
21-14	3295-3299	with	_	_	_	_
21-15	3300-3305	IL-33	substance	giv	coref	22-13
21-16	3306-3307	.	_	_	_	_

#Text=By using a panel of tumor cell lines , we show that IL-33 promotes tumoricidal functions of eosinophils in vitro and in vivo in a cell adhesion-dependent manner , through the integrin CD11b/CD18 and by inducing lytic granule convergence to the immune synapse .
22-1	3308-3310	By	_	_	_	_
22-2	3311-3316	using	_	_	_	_
22-3	3317-3318	a	object[175]	new[175]	_	_
22-4	3319-3324	panel	object[175]	new[175]	_	_
22-5	3325-3327	of	object[175]	new[175]	_	_
22-6	3328-3333	tumor	object[175]|object[177]	new[175]|new[177]	_	_
22-7	3334-3338	cell	object[175]|place|object[177]	new[175]|giv|new[177]	coref	22-26
22-8	3339-3344	lines	object[175]|object[177]	new[175]|new[177]	_	_
22-9	3345-3346	,	_	_	_	_
22-10	3347-3349	we	person	giv	ana	23-1
22-11	3350-3354	show	_	_	_	_
22-12	3355-3359	that	_	_	_	_
22-13	3360-3365	IL-33	abstract	giv	coref	23-12
22-14	3366-3374	promotes	_	_	_	_
22-15	3375-3386	tumoricidal	abstract[180]	giv[180]	_	_
22-16	3387-3396	functions	abstract[180]	giv[180]	_	_
22-17	3397-3399	of	abstract[180]	giv[180]	_	_
22-18	3400-3411	eosinophils	abstract[180]|substance[181]	giv[180]|giv[181]	_	_
22-19	3412-3414	in	abstract[180]|substance[181]	giv[180]|giv[181]	_	_
22-20	3415-3420	vitro	abstract[180]|substance[181]	giv[180]|giv[181]	_	_
22-21	3421-3424	and	_	_	_	_
22-22	3425-3427	in	_	_	_	_
22-23	3428-3432	vivo	_	_	_	_
22-24	3433-3435	in	_	_	_	_
22-25	3436-3437	a	abstract[183]	giv[183]	_	_
22-26	3438-3442	cell	place|abstract[183]	giv|giv[183]	coref	23-15
22-27	3443-3461	adhesion-dependent	abstract[183]	giv[183]	_	_
22-28	3462-3468	manner	abstract[183]	giv[183]	_	_
22-29	3469-3470	,	abstract[183]	giv[183]	_	_
22-30	3471-3478	through	abstract[183]	giv[183]	_	_
22-31	3479-3482	the	abstract[183]|object[184]	giv[183]|new[184]	_	_
22-32	3483-3491	integrin	abstract[183]|object[184]	giv[183]|new[184]	_	_
22-33	3492-3502	CD11b/CD18	abstract[183]|object[184]	giv[183]|new[184]	_	_
22-34	3503-3506	and	_	_	_	_
22-35	3507-3509	by	_	_	_	_
22-36	3510-3518	inducing	_	_	_	_
22-37	3519-3524	lytic	event[186]	new[186]	_	_
22-38	3525-3532	granule	abstract|event[186]	new|new[186]	_	_
22-39	3533-3544	convergence	event[186]	new[186]	_	_
22-40	3545-3547	to	event[186]	new[186]	_	_
22-41	3548-3551	the	event[186]|place[188]	new[186]|new[188]	_	_
22-42	3552-3558	immune	event[186]|abstract|place[188]	new[186]|giv|new[188]	_	_
22-43	3559-3566	synapse	event[186]|place[188]	new[186]|new[188]	_	_
22-44	3567-3568	.	_	_	_	_

#Text=Our data provide mechanistic insights into eosinophil anti-tumor activities stimulated by IL-33 that involve cell contact and directional secretion of granules toward target tumor cells enhancing killing efficiency .
23-1	3569-3572	Our	person|abstract[190]	giv|new[190]	_	_
23-2	3573-3577	data	abstract[190]	new[190]	_	_
23-3	3578-3585	provide	_	_	_	_
23-4	3586-3597	mechanistic	abstract[191]	new[191]	_	_
23-5	3598-3606	insights	abstract[191]	new[191]	_	_
23-6	3607-3611	into	abstract[191]	new[191]	_	_
23-7	3612-3622	eosinophil	abstract[191]|abstract[193]	new[191]|giv[193]	_	_
23-8	3623-3633	anti-tumor	abstract[191]|abstract|abstract[193]	new[191]|new|giv[193]	_	_
23-9	3634-3644	activities	abstract[191]|abstract[193]	new[191]|giv[193]	_	_
23-10	3645-3655	stimulated	_	_	_	_
23-11	3656-3658	by	_	_	_	_
23-12	3659-3664	IL-33	substance	giv	_	_
23-13	3665-3669	that	_	_	_	_
23-14	3670-3677	involve	_	_	_	_
23-15	3678-3682	cell	object|abstract[196]	giv|new[196]	_	_
23-16	3683-3690	contact	abstract[196]	new[196]	_	_
23-17	3691-3694	and	_	_	_	_
23-18	3695-3706	directional	abstract[197]	giv[197]	_	_
23-19	3707-3716	secretion	abstract[197]	giv[197]	_	_
23-20	3717-3719	of	abstract[197]	giv[197]	_	_
23-21	3720-3728	granules	abstract[197]|object[198]	giv[197]|giv[198]	_	_
23-22	3729-3735	toward	abstract[197]|object[198]	giv[197]|giv[198]	_	_
23-23	3736-3742	target	abstract[197]|object[198]|object[200]	giv[197]|giv[198]|giv[200]	_	_
23-24	3743-3748	tumor	abstract[197]|object[198]|abstract|object[200]	giv[197]|giv[198]|giv|giv[200]	_	_
23-25	3749-3754	cells	abstract[197]|object[198]|object[200]	giv[197]|giv[198]|giv[200]	_	_
23-26	3755-3764	enhancing	_	_	_	_
23-27	3765-3772	killing	_	_	_	_
23-28	3773-3783	efficiency	abstract	new	_	_
23-29	3784-3785	.	_	_	_	_
